BioCardia, Inc.
BioCardia (Nasdaq: BCDA) is a clinical-stage company developing cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its CardiAMP platform uses a patient’s own bone marrow mononuclear cells and is being studied for ischemic heart failure with reduced ejection fraction and chronic myocardial… From the company’s description.
In fiscal 2025, BioCardia, Inc. reported a net loss of $8.23M. Operations used $7.44M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BioCardia, Inc. does
In the company’s own words
BioCardia (Nasdaq: BCDA) is a clinical-stage company developing cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its CardiAMP platform uses a patient’s own bone marrow mononuclear cells and is being studied for ischemic heart failure with reduced ejection fraction and chronic myocardial ischemia with refractory angina. Its CardiALLO allogeneic mesenchymal stem cell therapy is being developed for ischemic heart failure, while PulmALLO is intended for acute respiratory distress syndrome. The company’s Helix catheter system enables minimally invasive, targeted delivery of biologic agents to the heart; BioCardia also partners with other developers and provides related services. Its Morph product line includes steerable vascular access catheters, including products cleared for specified procedures. BioCardia manufactures allogeneic cells and certain devices for clinical development, while a partner manufactures the CardiAMP cell-processing platform. If approved, the company plans to market its cardiac cell therapies through specialist-focused sales in the United States and through direct sales or a distribution partner in Japan.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SUNNYVALE, CA
- Fiscal year end
- December
- CIK
- 925741
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BioCardia, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BioCardia, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BioCardia, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BioCardia, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BioCardia, Inc.'s last four quarterly filings that the numbers alone won't show?”